We further investigated whether the activation of FGF18 inhibits renal carcinogenesis by regulating epithelial-mesenchymal transition (EMT), which aimed to identify FGF18 as novel prognostic biomarkers and therapeutic targets for clinical intervention of ccRCC. This evidence concerns the gene FGF18 and nonpapillary renal cell carcinoma.